Premium
Risk of glaucoma and treatment with systemic antihypertensive treatment – A nationwide study
Author(s) -
Horwitz A.,
Jeppesen J.,
TorpPedersen C.,
Kolko M.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0656
Subject(s) - medicine , glaucoma , antihypertensive drug , medical prescription , population , ocular hypertension , glaucoma medication , blood pressure , ophthalmology , pharmacology , environmental health
Purpose The aim of the study was to investigate the co‐morbidity of antihypertensive treatment and glaucoma in the Danish population throughout 16 years. Methods The study population comprised of all individuals living in Denmark in the period 1996–2012. The National Prescription Registry was used to identify all claimed prescriptions for glaucoma medication and antihypertensive drugs. Duration analysis models were employed to investigate the associations between antihypertensive treatments and the risk of development of glaucoma. A total of 26,596 observations were used in the estimated risk of developing glaucoma when treated with Calcium channel blockers ( CCB ), Angiotensin‐converting‐enzyme inhibitors ( ACEI ), Angiotensin II receptor blockers ( ARB ), Beta blockers ( BB ) or Diuretics ( DR ). Results An average age at onset for hypertension was 60.3 years (range: 0–109 years; 55.6% female). A total of 3.2% of all patients treated with antihypertensive drugs were diagnosed with glaucoma. The study found that antihypertensive treatment are associated with the risk of developing glaucoma. The risk of glaucoma increased significantly with age and was most strongly associated with ACEI , ARB , and CCB treatment. Conclusions Antihypertensive drugs are strongly associated with glaucoma.